Citations

Showing 10 of 108162 citations.

Clinical Impact of Secondary Risk Factors in TTN -Mediated Dilated Cardiomyopathy
Giudicessi, John R. , Shrivastava, Sanskriti , Ackerman, Michael J. , Pereira, Naveen L.

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 19, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circgen.120.003240 | PMID 33866824 Get It

Real-World Characteristics and Outcomes of Advanced Non-Small-Cell Lung Cancer Patients with EGFR Exon 19 Deletions or Exon 21 Mutations
Winfree, Katherine B. , Molife, Cliff , Peterson, Patrick , Chen, Yongmei , Visseren‐Grul, Carla , Leusch, Mark S. , Beyrer, Julie , Dimou, Anastasios , Peterson, Patrick M , Visseren-Grul, Carla M , Dimou, Anastasios

Mayo Clinic

Future Oncology | April 19, 2021 | Volume: 17 | Issue: 22 | Pages: 2867-2881

10.2217/fon-2021-0218 | PMID 33866796 Get It

Tsunami of economic turmoil to hit the healthcare in 2021-2022: COVID-19 pandemic is just an earthquake
Arredondo, Enrique , Kashyap, Rahul , Surani, Salim , Kashyap, Rahul , Surani, Salim

Mayo Clinic

Hospital Practice | April 19, 2021 | Volume: 49 | Issue: 4 | Pages: 232-239

10.1080/21548331.2021.1917896 | PMID 33866912 Get It

Development of an electronic conversation aid to support shared decision making for children with acute otitis media
Anderson, Jana L. , Silva, Lucas Oliveira J. e , Brito, Juan P. , Hargraves, Ian , Oliveira J E Silva, Lucas , Hargraves, Ian G, Brito, Juan P , Hess, Erik P.

Mayo Clinic

JAMIA Open | April 19, 2021 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/jamiaopen/ooab024 | PMID 33898937 Get It

Abstract Objective The overuse of antibiotics for acute otitis media (AOM) in children is a healthcare quality issue in part arising from conflicting parent and physician understanding of the risks and benefits of antibiotics for AOM. Our objective was to develop a conversation aid that supports shared decision making (SDM) with parents of children who are diagnosed with non-severe AOM in the acute care setting. Materials and Methods We developed a web-based encounter tool following a human-centered design approach that includes active collaboration with parents, clinicians, and designers using literature review, observations of clinical encounters, parental and clinician surveys, and interviews. Insights from these processes informed the iterative creation of prototypes that were reviewed and field-tested in patient encounters. Results The ear pain conversation aid includes five sections: (1) A home page that opens the discussion on the etiologies of AOM; (2) the various options available for AOM management; (3) a pictograph of the impact of antibiotic therapy on pain control; (4) a pictograph of complication rates with and without antibiotics; and (5) a summary page on management choices. This open-access, web-based tool is located at www.earpaindecisionaid.org. Conclusions We collaboratively developed an evidence-based conversation aid to facilitate SDM for AOM. This decision aid has the potential to improve parental medical knowledge of AOM, physician/parent communication, and possibly decrease the overuse of antibiotics for this condition.
Global Differences in Heart Failure With Preserved Ejection Fraction
Claggett, Brian , Jackson, Alice M. , Køber, Lars , Chopra, Vijay , Chen, Chen‐Huan , Maggioni, Aldo P. , Martínez, Felipe A. , Pieske, Burkert , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Rizkala, Adel R. , Inubushi-Molessa, Akiko, Lefkowitz, Martin, Shi, Victor , McMurray, John J.V. , Solomon, Scott D. , Investigators, on behalf of the PARAGON-HF, Maggioni, Aldo P , McMurray, John J V , Køber, Lars , Tromp, Jasper , Liu, Jiankang , Jhund, Pardeep S. , Jr., Jiri Widimsky , Boytsov, S. А. , Anand, Inder S. , Ge, Junbo , Packer, Milton , Pfeffer, Marc Alan , Zile, Michael R. , Solomon, Scott David , Lam, Carolyn S.P. , Investigators, on behalf of the PARAGON-HF

Mayo Clinic

Circulation: Heart Failure | April 19, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.120.007901 | PMID 33866828 Get It

Background: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem with important regional differences. We investigated these differences in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF), the largest and most inclusive global HFpEF trial. Methods: We studied differences in clinical characteristics, outcomes, and treatment effects of sacubitril/valsartan in 4796 patients with HFpEF from the PARAGON-HF trial, grouped according to geographic region. Results: Regional differences in patient characteristics and comorbidities were observed: patients from Western Europe were oldest (mean 75±7 years) with the highest prevalence of atrial fibrillation/flutter (36%); Central/Eastern European patients were youngest (mean 71±8 years) with the highest prevalence of coronary artery disease (50%); North American patients had the highest prevalence of obesity (65%) and diabetes (49%); Latin American patients were younger (73±9 years) and had a high prevalence of obesity (53%); and Asia-Pacific patients had a high prevalence of diabetes (44%), despite a low prevalence of obesity (26%). Rates of the primary composite end point of total hospitalizations for HF and death from cardiovascular causes were lower in patients from Central Europe (9 per 100 patient-years) and highest in patients from North America (28 per 100 patient-years), which was primarily driven by a greater number of total hospitalizations for HF. The effect of treatment with sacubitril-valsartan was not modified by region (interaction P >0.05). Conclusions: Among patients with HFpEF recruited worldwide in PARAGON-HF, there were important regional differences in clinical characteristics and outcomes, which may have implications for the design of future clinical trials. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01920711.
Schistosomiasis prevalence and low-cost diagnostics in rural Northwestern Madagascar: a pilot study
Robinson, Kyle E. , Grewal, Eric P. , Pritt, Bobbi S. , Lloyd, Margaret , Stephano, Adriantiano M., Fardine, Mamantsara, Brumble, Lisa , Pritt, Bobbi S , Grewal, Eric P , Lloyd, Margaret, Libertin, Claudia R.

Mayo Clinic

Journal of Global Health Reports | April 19, 2021 | Volume: 5 | Issue: No issue available | Pages: No page available

10.29392/001c.22123 Get It

Background Schistosomiasis is a parasitic disease that affects the health of hundreds of millions of people worldwide. Affordable diagnostic methods are necessary for developing countries to monitor schistosomiasis rates and treat infected individuals, particularly in, Madagascar, a country with the world’s fifth highest rate of schistosomiasis. Methods We established the prevalence rate of schistosomiasis among the local population served by a clinic in rural northwestern Madagascar. Additionally, we compared different low-cost methods for schistosomiasis detection, including empirical diagnostic methods in use before this study. 500 patients were recruited in this study, of whom 380 received three tests—urine microscopy, point-of-care circulating cathodic antigen (POC-CCA) testing, and urinalysis to screen for Schistosoma haematobium and Schistosoma mansoni. Results By combining these modalities, we recorded a schistosomiasis prevalence rate of 64.47%, which was significantly higher than the 4.84% of patients who were diagnosed and treated through previous empirical methods. Conclusions Our results indicate that screening tests are a necessary component of schistosomiasis control programs. The clinic continued to use urinalysis strip testing and urine microscopy to detect schistosomiasis after this study and decided to discontinue the use of POC-CCA S. mansoni urine testing because of cost. Increased awareness of schistosomiasis resulting from this screening program led to the installation of multiple infrastructure projects in local communities to improve access to potable water, demonstrating community benefits of schistosomiasis screening that extend beyond the identification of infected individuals.
Popliteal entrapment syndrome—The case for a new classification
Jayaraj, Arjun , Gloviczki, Péter , Duncan, Audra A. , Kalra, Manju , Bower, Thomas C., DeMartino, Randall R. , Oderich, Gustavo S. , Gloviczki, Péter

Mayo Clinic

Vascular | April 19, 2021 | Volume: 30 | Issue: 2 | Pages: 285-291

10.1177/17085381211007612 | PMID 33866882 Get It

Objectives To assess the ability of the current classification system for popliteal entrapment syndrome to accurately capture all patients, and if not, to design an all-inclusive new classification. Methods Retrospective review of all interventions performed for popliteal entrapment syndrome between 1994 and 2013 at our institution was performed. Preoperative imaging and intraoperative findings were used to establish the compressive morphology of popliteal entrapment syndrome. Patients were categorized, when possible, into six types of the current classification system (Rich classification, modified by Levien) and into seven types of a new classification. Results Sixty-seven limbs of 49 patients were operated on for unilateral (31) or bilateral (18) popliteal entrapment syndrome. The current classification system captured the anatomy of only 43 (64%) of 67 limbs with popliteal entrapment syndrome. Compressive morphologies without a defined class included aberrant insertion of the lateral head of gastrocnemius muscle, muscle slip originating from the lateral head of gastrocnemius or hamstrings, hypertrophied hamstring muscle, abnormal fibrous bands, perivascular connective tissue, and prominent lateral femoral condyle. The new classification captured 100% of the limbs with popliteal entrapment syndrome. Conclusions Current classification of popliteal entrapment syndrome is inadequate as more than one-third of the cases reviewed fell outside of the standard classification system. Consideration of a more inclusive new anatomic classification system is warranted.
Trend and Geographic Disparities in the Mortality Rates of Primary Systemic Vasculitis in the United States from 1999 to 2019: A Population-Based Study
Rodríguez-Pla, Alicia , Rosselló-Urgell, José, Rodriguez-Pla, Alicia

Mayo Clinic

Journal of Clinical Medicine | April 18, 2021 | Volume: 10 | Issue: 8 | Pages: 1759

10.3390/jcm10081759 | PMID 33919526 Get It

The current data on rates and geographic distribution of vasculitis mortality are limited. We aimed to estimate the mortality rates of primary systemic vasculitis and its geographic distribution using recent population data in the United States. The mortality rates of vasculitis from 1999 to 2019 were obtained from the Center for Disease Control (CDC) Wonder Multiple Cause of Death (MCD). The age-adjusted rates per million for vasculitis as MCD and as an underlying cause of death (UCD) were calculated by state using demographics. A joinpoint regression analysis was applied to evaluate trends over time. The age-adjusted mortality rate of vasculitis as MCD was 4.077 (95% CI: 4.029–4.125) and as a UCD was 1.888 per million (95% CI: 1.855–1.921). Since 1999, mortality rates have progressively decreased. The age-adjusted mortality rate was higher in females than in males. The highest mortality rate for vasculitis as MCD was in White patients (4.371; 95% CI: 4.317–4.424). The northern states and areas with lower populations had higher mortality rates. We found a trend of progressive decreases in the mortality rates of vasculitis, as well as gender, racial, and geographic disparities. Further analyses are warranted to better understand the factors associated with these disparities in order to implement targeted public health interventions to decrease them.
Disclosure slide at the Society of Surgical Oncology Annual Symposium—Is there room for improvement?
Bagaria, Sanjay P. , Sabel, Michael S. , Sabel, Mike , Bagaria, Sanjay P

Mayo Clinic

Journal of Surgical Oncology | April 18, 2021 | Volume: 123 | Issue: 8 | Pages: 1677-1678

10.1002/jso.26502 | PMID 33866569 Get It

Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation
Watt, Kymberly D. , Rizk, Monika, Jaruvongvanich, Pete, Sánchez, William , Venkatesh, Sudhakar K. , Bamlet, Heather , Tiedtke, Kathryn, Malhi, Harmeet , Grothe, Karen, Clark, Matthew M. , Venkatesh, Sudhakar K , Malhi, Harmeet , Acosta Cardenas, Andres, Sanchez, William , Heimbach, Julie K. , Port, John D. , Cárdenas, Andrés , Mundi, Manpreet S. , Dayyeh, Barham K. Abu

Mayo Clinic

Liver Transplantation | April 18, 2021 | Volume: 27 | Issue: 9 | Pages: 1239-1247

10.1002/lt.26074 | PMID 33866660 Get It

The efficacy and safety of a fluid‐filled intragastric balloon (IGB) for weight loss in patients with cirrhosis on the liver transplantation (LT) waiting list is unknown. We enrolled stable compensated patients with body mass index >35 kg/m2 and on the waiting list for IGB placement endoscopically for a maximum of 6 months. A total of 8 patients (7 men) aged mean ± SD, 56 ± 4.6 years with Model for End‐Stage Liver Disease–sodium (MELD‐Na) scores 14.1 ± 3.4 experienced weight reduction (146 ± 22.2 kg versus 127 ± 21.6 kg [P = 0.005] with IGB in place and 130 ± 24.6 kg [P = 0.014] at 6 months), with a total body weight loss of 12.2% ± 8.8% with IGBs in place and 10.9% ± 8.9% at 6 months. Body fat decreased from 48.6% ± 5.8% to 40.6% ± 6.4% (P = 0.001) and lean mass increased from 51.3% ± 6% to 59.4% ± 6.4% (P = 0.001). No change in MELD‐Na scores occurred (P = 0.770). Early balloon retrieval was attributed to accommodative symptoms (n = 2) and liver decompensation (n = 1). Mallory Weiss tears (n = 3), but no portal hypertensive bleeding, occurred. Liver decompensation and/or hepatocellular carcinoma (HCC) developed in 3 patients. A total of 4 patients with LT ± sleeve gastrectomy maintained overall weight loss. Of 4 patients who did not receive transplants, 2 experienced weight regain. IGB results in short‐term weight loss in patients with cirrhosis awaiting LT, with body fat loss without lean mass loss. Adverse effects were common. Decompensation and HCC did occur, with uncertainty of the relation to weight loss, and thus careful patient selection and close follow‐up are required.